Skye Bioscience, Inc. (SKYE) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company developing next-generation molecules to treat obesity and metabolic diseases. The primary product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting the CB1 receptor. The company reported for the quarterly period ended September 30, 2024. Skye has no revenue-generating operations and is focused on advancing its clinical pipeline, specifically the Phase 2 CBeyond trial for nimacimab.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,898,297) | $(24,945,834) | $(16,820,644) | $(33,224,854) |
| Operating Loss | $(4,968,796) | $(24,705,766) | $(19,526,617) | $(30,648,916) |
| Cash & Equivalents (End of Period) | $67,412,614 | $5,126,245 | $67,412,614 | $5,126,245 |
| Restricted Cash | $9,080,202 | $9,084,799 | $9,080,202 | $9,084,799 |
| Working Capital | $74,184,006 | N/A | $74,184,006 | N/A |
| Stockholders' Equity | $75,803,375 | $1,695,258 | $75,803,375 | $1,695,258 |
Debt & Liquidity: As of September 30, 2024, the company had no outstanding convertible notes after the full conversion of a $5 million related-party note in August 2024. Total liabilities were $5.73 million, primarily consisting of accrued legal contingencies and operating lease liabilities. The company raised $83.6 million in net proceeds from PIPE financings in January and March 2024.
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: The net loss for Q3 2024 decreased by approximately $21 million compared to Q3 2023. This improvement is largely driven by a $4.55 million favorable change in the estimate for legal contingencies and the absence of a $21.2 million one-time expense for the acquisition of an IPR&D asset (nimacimab) that occurred in Q3 2023.
- Increased Operating Expenses: Research and Development (R&D) expenses increased by 289% year-over-year in Q3 (from $1.25M to $4.88M) due to the commencement of the Phase 2 CBeyond clinical trial. General and Administrative (G&A) expenses increased by 107% (from $2.24M to $4.64M) due to increased headcount and stock-based compensation.
- Capital Position: Cash and cash equivalents increased from $1.26 million at year-end 2023 to $67.4 million at September 30, 2024, following successful equity financings.
- Asset Sales: The company recorded a gain of $1.22 million from the sale of the AVI building and collections from the divestiture of VDL during the nine months ended September 30, 2024.
Outlook, Risks, and Management Commentary
- Clinical Progress: The Phase 2 CBeyond trial for nimacimab is ongoing with 120 patients across 18 sites. The company expects to meet 50% enrollment by the end of 2024, with interim data expected in Q2 2025 and topline data in Q4 2025.
- Program Discontinuation: In June 2024, the company discontinued its ocular program (SBI-100) after the Phase 2a trial failed to achieve statistical significance. Resources have been redirected to the metabolic program.
- Legal Contingencies: A significant risk factor involves the Wendy Cunning vs. Skye Bioscience lawsuit. In October 2024 (subsequent to the reporting period), the Ninth Circuit Court of Appeals vacated the original judgment and remanded the case for a new trial. The company expects to recover the $9.08 million appeal bond by the end of 2024, which will further extend its cash runway.
- Liquidity Runway: Management believes current cash resources are sufficient to fund operations for at least 12 months. The company has an At-The-Market (ATM) agreement to sell up to $100 million of common stock, though no shares have been sold under this agreement to date.
- Stock-Based Compensation: Significant stock-based compensation expense ($6.23 million YTD 2024) was recognized due to the vesting of RSUs tied to market-based performance milestones.
Key Facts for Investor Verification
- Legal Bond Release: Verify the timeline and confirmation of the release of the $9.08 million restricted cash (appeal bond) following the Ninth Circuit's October 2024 decision.
- Clinical Enrollment: Monitor the progress of the Phase 2 CBeyond trial to ensure the 50% enrollment target is met by year-end 2024 as projected.
- Capital Expenditures: Review the burn rate relative to the $67.4 million cash balance to confirm the 12-month runway estimate remains valid given the scale-up of clinical operations.
- Equity Dilution: Track the conversion of pre-funded warrants and potential future issuances under the ATM agreement or PIPE financings.
- Insurance Recovery: Monitor the status of the lawsuit against Partner Re Ireland Insurance DAC regarding coverage for legal expenses related to the Cunning Lawsuit.